|
Search |
Citigroup upgraded Vertex Pharmaceuticals (NASDAQ:VRTX) to Buy from Hold this morning and increased their price target on shares of the company to $60 from $59.00. The bank cited the solid launch of Incivek and solid Q2 earnings results.
The bank also increased their 2012 GAAP EPS estimates on shares of the company $0.11 to $5.19.
Vertex Pharmaceuticals has a potential upside of 15.9% based on a current price of $50.54 and an average consensus analyst price target of $58.56.
From FNNO.com, this is the Financial News Network. I’m Cleo
Stiller-Farrell and this is your Midweek Market Wrap Up. The British
Bankers’ Association, which has the supervisory role of setting the
influential Libor rates, announced that it would be willing to give up
its...
The Wall Street Journal reports that home prices showed their best year-to-date gains since 2005, up 5.9% through July, signaling the housing market's steady march toward recovery. Also from the Wall Street Journal, IBM (IBM) will increase its efforts to sell so-called cloud computing services...
CEO Marissa Mayer is bringing in some more new blood to Yahoo!, tapping Ken Goldman as the company's new Chief Financial Officer. Goldman's appointment will take effect on October 22nd.
Goldman served as CFO at his most recent employer, Fortinet, having worked at Siebel Systems, Sybase,...
